Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Pulse Biosciences CS (PLSE)

Pulse Biosciences CS (PLSE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Insider Purchase: Director at $PLSE (PLSE) Buys 50,000 Shares Quiver Quantitative, Inc. - Sat Dec 14, 4:52AM CST

ROBERT W DUGGAN, a director at $PLSE ($PLSE), bought 50,000 shares of the company on 12-11-2024. This trade was reported by Quiver Quantitative using data from a recent SEC filing. This increased their...

PLSE : 17.40 (-3.23%)
Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer Business Wire - Wed May 3, 2023

Pulse Biosciences, Inc. (Nasdaq: PLSE), Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of...

PLSE : 17.40 (-3.23%)
Pulse Biosciences Announces $65 Million Private Placement Business Wire - Mon May 1, 2023

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology and proprietary CellFX System® for the treatment of atrial...

PLSE : 17.40 (-3.23%)
Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023 Business Wire - Thu Apr 27, 2023

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation,...

PLSE : 17.40 (-3.23%)
Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results Business Wire - Thu Mar 30, 2023

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation,...

PLSE : 17.40 (-3.23%)
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023 Business Wire - Thu Mar 2, 2023

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation,...

PLSE : 17.40 (-3.23%)
Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium Business Wire - Thu Feb 2, 2023

Pulse Biosciences, Inc . (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation,...

PLSE : 17.40 (-3.23%)
Pulse Biosciences Reports Third Quarter 2022 Financial Results Business Wire - Thu Nov 10, 2022

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company and creator of the unique CellFX® System which harnesses and effectively controls the application of Nano-Pulse Stimulation™...

PLSE : 17.40 (-3.23%)
Pulse Biosciences Schedules Third Quarter 2022 Financial Results Conference Call for November 10, 2022 Business Wire - Thu Oct 27, 2022

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report...

PLSE : 17.40 (-3.23%)
Pulse Biosciences Announces Positive Clinical Data on Nano-Pulse Stimulation Procedure for Low-Risk Basal Cell Carcinoma Lesions Business Wire - Thu Oct 6, 2022

Pulse Biosciences, Inc . (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced positive clinical...

PLSE : 17.40 (-3.23%)

Barchart Exclusives

Why This Dividend Stock Just Scored a Rare Upgrade Barchart - 51 minutes ago
Bristol Myers Squibb, a global biopharma company, has received a rare upgrade from Jefferies due to its promising pipeline and strategic partnerships. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot